Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine (Q68171769)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

title

Comparison of verapamil, diltiazem, and labetalol on the bioavailability and metabolism of imipramine (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

Comparison of Verapamil, Diltiazem, and Labetalol on the Bioavailability and Metabolism of Imipramine (English)

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

15 October 2022

1 reference

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

15 October 2022

1 reference

D. J. Hermann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

T. F. Krol

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

G. E. Dukes

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

E. K. Hussey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

M. Danis

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

Y. H. Han

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

J. R. Powell

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

L. J. Hak

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1613128

15 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1613128

15 October 2022

publication date

1 February 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

22 September 2019

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1552-4604.1992.tb03823.x

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

http://onlinelibrary.wiley.com/wol1/doi/10.1002/j.1552-4604.1992.tb03823.x/fullpdf

15 October 2022

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

The Journal of Clinical Pharmacology

15 October 2022

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

page(s)

176-183

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

Psychotropic drug use and the risk of hip fracture

22 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.

15 October 2022

2

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy

15 October 2022

3

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

The effect of coadministration of verapamil on the pharmacokinetics and metabolism of quinidine

15 October 2022

5

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Digoxin-verapamil interaction

15 October 2022

6

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Combined alpha adrenoceptor antagonism and calcium channel blockade in normal subjects

15 October 2022

7

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Inhibition of theophylline elimination by diltiazem therapy

15 October 2022

8

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

The diltiazem-digoxin interaction

15 October 2022

9

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists in related to their lipid solubility [letter]

15 October 2022

10

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Impairment of antipyrine clearance in humans by propranolol

15 October 2022

12

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Effects of metoprolol and propranolol on theophylline elimination

15 October 2022

13

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Failure of ‘therapeutic’ doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine

15 October 2022

14

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Effect of propranolol on pharmacokinetics and acute electrocardiographic changes following intravenous quinidine in humans

15 October 2022

15

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Inhibition of antipyrine metabolism by beta-adrenoceptor antagonists

15 October 2022

16

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Comparative evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and indocyanine green clearances

15 October 2022

17

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

High‐Performance Liquid Chromatographic Assay for Imipramine, Desipramine, and Their 2‐Hydroxylated Metabolites

15 October 2022

18

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

15 October 2022

19

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

15 October 2022

20

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase

15 October 2022

21

1 reference

https://api.crossref.org/works/10.1002/J.1552-4604.1992.TB03823.X

15 October 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1613128%20AND%20SRC:MED&resulttype=core&format=json

22 September 2019

1 reference